VPA10810/018/003

Pimotab 5 mg chewable tablets for dogs

Variation	Summary	Date
Vet - G.I.15 z)	VRA-R - Vet - G.I.15 z) - - Vet - G.I.15 z) - Changes to the labelling or the package leaflet which are not connected with the summary of product characteristics - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	08/09/25
Vet - C10 a)	VNRA - Vet - C10 a) - - Vet - C10 a) - Changes to the labelling or the package leaflet which shall not be connected with the SPC: administrative information concerning the holder's representative	25/06/25
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	02/04/25
Vet - F.II.f.1 a) 1.	VRA-R - Vet - F.II.f.1 a) 1. - a) Extension of the shelf life of the finished product 1. As packaged for sale (supported by real time data) - F.II.f.1 a) 1. Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	10/06/24
B.I.a.1.b	II - B.I.a.1.b - b) Introduction of a manufacturer of the active substance supported by an ASMF - B.I.a.1.b - QUALITY CHANGES - ACTIVE SUBSTANCE - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - Introduction of a manufacturer of the active substance supported by an ASMF	25/07/22